Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Core Insights - Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases affecting bone health and blood vessel function [3][4] - The company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1][2] Company Overview - Inozyme Pharma specializes in the PPi-Adenosine Pathway, where the ENPP1 enzyme plays a crucial role in generating inorganic pyrophosphate (PPi) and adenosine, which are vital for regulating mineralization and controlling smooth muscle cell proliferation in blood vessels [3] - Disruptions in this pathway can lead to severe conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL) [3] Lead Candidate - The lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) aimed at increasing levels of PPi and adenosine [4] - INZ-701 is currently in clinical development for treating ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, targeting the underlying issues of pathological mineralization and intimal proliferation [4]